Compare Flux Power Holdings Inc (FLUX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FLUX trades at $0.47, down 3.96% today, with bearish technical signals from moving averages. The company reported Q4 2026 revenue of $8.2M, beating expectations, but posted a net loss of $6.67M for 2025. Recent news highlights a rejected acquisition proposal from Solidion Technology. Despite negative profitability metrics, all six covering analysts maintain Buy ratings.

FLUX faces significant execution risks with negative margins and cash flow challenges, but analyst consensus remains bullish. The stock's current valuation at 0.22 P/S suggests potential upside if operational improvements materialize. Key risks include sustained losses and competitive pressures in the energy storage sector.

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.